drugset / Trial / NCT03226899
A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment
RandomizedParallel-groupTriple-blindTreatment
Summary
This study evaluates the safety and efficacy of lesinurad administered with an XOI versus a placebo plus an XOI in gout participants who have moderate renal impairment and who are not at target level of serum urate (sUA).
Timeline
- Start
- 2017-07-19
- Primary completion
- 2019-02-25
- Completion
- 2019-02-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lesinurad | Small molecule | 200 mg | Oral |
| Comparator | Allopurinol | Small molecule | — | — |
| Comparator | Colchicine | Small molecule | 0.5 mg | — |
| Comparator | Colchicine | Small molecule | 0.6 mg | — |
| Comparator | Febuxostat | Small molecule | — | — |